GlassScriptPhysician profile
Mazen K Khalil
NPI 1679725808
$5,138.47
in general payments reported to CMS, 2019-2025
30 companies · $716 in 2025
The $716 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,338 · 2020: $41.83 · 2021: $317 · 2022: $650 · 2023: $659 · 2024: $417 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,791.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,923.39 | 2019-2023 | Diamondback Coronary |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $387.17 | 2021-2025 | Lifevest |
| Medtronic, INC. | $308.29 | 2021-2025 | Micra, Onyx Frontier |
| Novartis Pharmaceuticals Corporation | $251.26 | 2019-2024 | |
| Penumbra, INC. | $249.30 | 2023 | Indigo System |
| E.R. Squibb & Sons, L.L.C. | $209.17 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $207.07 | 2021-2025 | Farxiga, Lokelma |
| Amgen INC. | $200.77 | 2019-2025 | Repatha |
| Abiomed | $200.11 | 2019-2025 | Impella |
| Edwards Lifesciences Corporation | $191.22 | 2019-2021 | |
| Cardiovascular Systems INC. | $156.16 | 2022 | |
| Pfizer INC. | $102.64 | 2019-2025 | |
| Boston Scientific Corporation | $98.94 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $95.55 | 2022-2025 | Verquvo |
| Shockwave Medical, INC | $85.92 | 2022-2023 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.25 | 2019-2025 | Jardiance |
| Cvrx, INC. | $66.10 | 2024-2025 | Barostim Neo System |
| Heartflow, INC. | $55.45 | 2024 | |
| Alnylam Pharmaceuticals INC. | $40.94 | 2021-2025 | Onpattro |
| Philips North America LLC | $37.64 | 2022 | |
| Janssen Pharmaceuticals, INC | $24.38 | 2019-2021 | |
| Novo Nordisk INC | $24.27 | 2025 | Wegovy |
| Medtronic Vascular, INC. | $21.03 | 2019 | |
| Baxter Healthcare | $19.62 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Janssen Biotech, INC. | $19.50 | 2024 | Talvey, Tecvayli |
| Sanofi-Aventis U.S. LLC | $19.36 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.98 | 2023 | Praluent, Evkeeza |
| Bayer Healthcare Pharmaceuticals INC. | $15.67 | 2025 | |
| Lantheus Medical Imaging, INC. | $15.54 | 2024 | |
| Lundbeck LLC | $14.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazen Khalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.